Kyntra Bio
Open
$7.17
Prev. Close
$6.99
High
$7.17
Low
$7.17
Market Snapshot
$28.85M
0.2
-11.84
$-96.77M
34
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2014-11-14. The firm is focused on development of novel therapies in oncology and rare disease. The firm continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2014-11-14. The firm is focused on development of novel therapies in oncology and rare disease. The firm continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
Recently from Cashu
Kyntra Bio's Innovation and Sustainability Strategy in Biotechnology Sector
Kyntra Bio's Strategic Positioning in the Biotech Landscape Kyntra Bio is poised to make significant strides within the biotechnology sector, particularly as advancements in gene editing and synthetic…
Kyntra Bio: Revolutionizing Biomanufacturing with Sustainability and Innovation in Life Sciences.
Kyntra Bio’s Innovative Approach to Biomanufacturing: A Game Changer in the Life Sciences Sector Kyntra Bio is at the forefront of revolutionizing biomanufacturing processes, a critical component in t…
Kyntra Bio's FG-3246 Trial Results Show Promise for Prostate Cancer Treatment Advancements
Kyntra Bio's Breakthrough in Prostate Cancer Treatment: FG-3246 Trial Results Hold Promise Kyntra Bio Inc., formerly known as Fibrogen, announces critical data from its Phase 1b/2 clinical trial inves…